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Adalimumab is a fully human immunoglobulin G1 monoclonal antibody against tumor necrosis factor
(TNF)-a that is increasingly used for the treatment of many autoimmune diseases. However, it has also
been reported that adalimumab can induce many adverse cutaneous reactions, including paradoxical
psoriasiform eruptions. We describe a patient with pustulosis palmoplantaris who developed four
cutaneous adverse reactions, including eczematous lesions, acneiform eruption, alopecia areata, and
urticaria during adalimumab treatment. A common histopathological ﬁnding in these acneiform and
urticarial lesions was the presence of eosinophilic inﬁltrates. Some authors assume that cross-regulation
between TNF-a and interferon-a may contribute to development of a clinical spectrum of cutaneous
reactions in predisposed individuals undergoing anti-TNF therapy. The use of different biologics,
including adalimumab, etanercept, and ustekinumab, did not seem to improve pustulosis palmoplantaris
disease activity in our patient.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Adalimumab is a fully human monoclonal antibody against tumor
necrosis factor (TNF)-a that is increasingly used for the treatment of
many autoimmune diseases, including psoriasis and pustulosis
palmoplantaris (PPP), owing to its efﬁcacy and safety. However, it
has also been reported that adalimumab induces various adverse
cutaneous reactions. We describe a patient with PPP who devel-
oped four unusual adverse cutaneous reactions during adalimumab
treatment.Case report
A 50-year-old Taiwanese male who was a smoker presented with
recurrent painful pustules with hyperkeratosis and desquamation
over his palms and soles since 2008 (Figure 1A,B). PPP was diag-
nosed. He had been treated with different conventional therapeutic
agents, including methotrexate, acitretin, cyclosporine, and topicalnt of Dermatology, National
h Road, Taipei 100, Taiwan.
iwanese Dermatological Associatiocorticosteroids, with limited effects. He had also experienced mild
elevation of liver enzymes due to methotrexate and complained of
headaches and hypertension due to high-dose cyclosporine. Hewas
unable to undergo regular phototherapy because he lived in a rural
area. He was referred to our hospital in 2009. After screening for
tuberculosis and hepatitis B, he received subcutaneous injections of
adalimumab (Humira, Abbott Laboratories, Abbott Park, IL, USA)
at a dose of 40 mg every other week in combination with metho-
trexate (15 mg/week).
However, within 1week after the third injection of adalimumab,
many mildly tender follicular erythematous papulonodules with
pustules developed over his face and trunk, especially over the
axillae, groin, and buttocks (Figure 2B). Histopathological exami-
nation of a skin biopsy from the left cheek revealed a follicular
pustule containing keratins with dense neutrophilic and eosino-
philic inﬁltrates. The eosinophils were located mainly in the peri-
follicular dermis, whereas the neutrophils and a few eosinophils
were located at the oriﬁce of the follicle. No bacterial clumps were
found (Figure 2C,D). A pus culture yielded small amounts of
coagulase-negative staphylococci and Propionibacterium acnes, and
inﬂamed acne was diagnosed. The peripheral eosinophil count was
within normal limits.
One week after the development of acneiform eruptions,
a generalized eczematous rash and itchy wheal-like papules andn. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 (A,B) Many pustules with hyperkeratosis and desquamation on the patient’s palms and soles.
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vidual urticarial lesions subsided within 24 hours, whereas the
eczematous lesions persisted beyond 24 hours (Figure 3). More-
over, several well-deﬁned hairless patches of up to coin size
appeared over his parietal scalp at the same time. No overlying
scalp skin changes were found and a hair pull test was positivewith
exclamation mark hairs (Figure 4). Alopecia areata (AA) was diag-
nosed clinically. The patient reported that he had not had previous
episodes of acne vulgaris, urticaria or AA. A skin biopsy from one of
the urticarial plaques over his shoulder showed perivascular and
interstitial inﬁltrates composed of eosinophils, lymphocytes, andFigure 2 (A,B) Many follicular-corresponding erythematous papules, pustules, and nodules
a follicular pustule containing keratins, and neutrophilic and eosinophilic inﬁltrates. Many n
(D) Most eosinophils were located in the perifollicular dermis (H&E, 200).neutrophils without vasculitis. Interstitial dermal edema was also
noted. The histopathological ﬁndings favored a hypersensitivity
reaction. When the fourth and ﬁfth doses of adalimumab were
given, all of the skin lesions became more severe. Therefore, we
discontinued adalimumab and prescribed doxycycline 100 mg
twice daily for the acneiform eruptions. Intra-lesional triamcino-
lone acetonide was also given for the larger inﬂamed nodules, with
good efﬁcacy. However, the urticarial eruptions responded poorly
to different oral antihistamines, including levocetirizine, fex-
ofenadine, and desloratadine. He was thus treated with metho-
trexate (15 mg/week) and cyclosporine (75 mg/day) because bothwere noted over the patient’s face, axillae, groin, and buttocks. (C) Pathology revealed
eutrophils and a few eosinophils were located at the oriﬁce of the follicle (H&E, 40).
Figure 3 (A,B) Generalized wheal-like papules and plaques with many eczematous patches over the patient’s trunk and extremities. (C,D) Close-up images of the urticarial and
eczematous lesions.
Figure 4 Several well-deﬁned hairless patches of up to coin size were noted over the
patient’s frontal and parietal scalp. No overlying scalp skin changes were found.
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urticaria.
The treatment was then changed to etanercept, a dimeric
TNF-a receptor fusion protein, and acitretin (20 mg/day). All of the
four cutaneous adverse reactions, including the eczematous
lesions, acneiform eruptions, AA, and urticaria, improved gradu-
ally, with clinical remission 1, 3, 4, and 7 months after their onset,
respectively (Figure 5). However, PPP disease activity persisted
despite a 5-month course of etanercept. He was then treated with
ustekinumab, a human anti-interleukin-12 and anti-interleukin-
23 monoclonal antibody, at a dose of 45 mg by subcutaneous
injection (in weeks 0 and 4) in combination with methotrexate
(15 mg/week), acitretin (20 mg/day), and low-dose cyclosporine
(75 mg/day). Unfortunately, he still experienced frequent recur-
rence of pustular eruptions on his palms and soles during the
2 months after the second injection of ustekinumab. He was thus
kept on cyclosporine and acitretin. The PPP skin lesions improved
gradually, with only occasional minor recurrence of pustules on
the soles 2 months after he started taking acitretin alone. He also
quit smoking during this period. We assume that he is currently in
remission from PPP.
Figure 5 Clinical course of adverse cutaneous reactions in the patient.
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Adalimumab is a fully human immunoglobulin G1 monoclonal
anti-TNF-a antibody that has shown efﬁcacy for the treatment of
many autoimmune diseases, including plaque-type psoriasis,
psoriatic arthritis, and PPP.1,2 A variety of cutaneous adverse reac-
tions have been reported during anti-TNF-a therapy, including
infusion reactions, injection site reactions, cutaneous infection,
eczema, atopic dermatitis, pruritus, drug-induced lupus eryth-
ematosus, new onset or exacerbation of psoriasiform lesions, and
hypersensitivity reactions.3e5 The prevalence of each skin lesion
varies among different studies.4,5 A prospective study of 150
patients with rheumatic diseases who were using TNF-a antago-
nists found that 35 (23%) of the 150 patients developed some sort of
adverse cutaneous reaction.6 However, most cutaneous reactions
occur during treatment for rheumatoid arthritis, Crohn’s disease,
and ankylosing spondylitis. Only isolated case reports and a few
case series have described adverse skin effects in patient with
psoriasis.
Acneiform eruption, urticaria, and AA following TNF-a antago-
nists are quite rare (Table 1).11,13e16,18,19e21,24 Eleven patients who
developed AA after anti-TNF-a agents have been reported in the
English literature, of whom ﬁve received adalimumab therapy.7e17Table 1 Literature review of clinical characteristics and outcomes for patients who deve
Skin reaction Case
No
Sex Age Diagnosis Onset after
adalimumab
Clinical featu
Alopecia
areata (AA)
1 F 23 Rheumatoid arthritis 2 months Patchy-type
2 M 43 Psoriatic arthritis 6 months Patchy-type
3 F 38 Rheumatoid arthritis 24 months AA totalis
4 F 30 Rheumatoid arthritis 9 months Patchy-type
5 F 52 Psoriatic arthritis 15 days Patchy-type
Urticaria 1 F 60 Rheumatoid arthritis 3 months Urticaria, an
and hypoten
2 F 41 Psoriasis 1 weeks Urticaria
3 F 31 Behcet’s disease 1 month Urticaria and
angioedema
4 M 32 Ankylosing spondylitis 1 month Urticaria
Acneiform
eruption
1 M 55 Pustular psoriasis 2 months Acneiform e
2 M 62 Rheumatoid arthritis 3 months Acneiform e
F ¼ female; M ¼ male; AA ¼ Alopecia areata; NA ¼ not available; IV ¼ intravenous.Although the exact mechanism for AA development during anti-
TNF-a therapy is unknown, it has been suggested that TNF-a
blockage could contribute to dysregulation of immune responses
leading to the development of AA.13 According to published reports,
only four patients have developed urticarial lesions after adali-
mumab therapy.18e21 In two cases, the urticaria was accompanied
by angioedema.18,20 However, no pathology was available for these
patients.
In addition to AA and urticaria, acneiform eruptions following
anti-TNF-a therapy are also rare. To the best of our knowledge, only
seven cases (ﬁve treated with inﬂiximab and two with adalimu-
mab) have been described in the English literature.22e25 Sun et al
reported on three patients with acneiform eruptions following
anti-TNF-a treatment, two of whom were receiving adalimumab
therapy.24 Most patients developed asymptomatic erythematous
follicular papules, pustules or nodules over the face and trunk 1e2
months after therapy initiation. Of the seven documented cases,
only two patients had underlying psoriasis. One case with plaque-
type psoriasis received inﬂiximab and another case with pustular
psoriasis received adalimumab. The severity of acneiform eruptions
varied. Some patients improved with doxycycline monotherapy,
whereas others needed isotretinoin to control the skin lesions. No
detailed histopathological descriptions of acneiform eruptions have
been documented previously. In our case, pathology revealed
a follicular pustule containing keratins with dense neutrophilic and
eosinophilic inﬁltrates.
The follicular eruptions in our patient showed eosinophilic
inﬁltration and thus drug-induced eosinophilic pustular folliculitis
was a possible differential diagnosis.26
However, eosinophils in eosinophilic pustular folliculitis are
predominantly within hair follicles, whereas the eosinophils in our
case were located mainly interstitially, with only a few eosinophils
at the oriﬁce of the follicle. We did not observe any eosinophilic
inﬁltration into the follicular epithelium or sebaceous glands.
Moreover, the clinical morphology was papulonodular lesions, and
not papular lesions alone.We added indomethacin to the treatment
for 2 months without efﬁcacy. Thus, acneiform eruption seems to
be a better diagnosis to cover the possibility of eosinophilic
pustular folliculitis. The signiﬁcance of the Propionibacterium acnes
in the acneiform eruptions in our patient is unclear, and might
represent an infection, colonization, or only contamination.We also
assumed that the acneiform eruption was an unusual hypersensi-
tivity reaction, and not true acne vulgaris.loped alopecia areata, urticaria, and acneiform eruptions after adalimumab therapy.
re Treatment Prognosis Reference
AA Topical dexamethasome Evolution to AA universalis 11
AA Potent topical
corticosteroids
Evolution to AA universalis 13
NA Evolution to AA universalis 14
AA Topical & systemic
corticosteroids
Minimal hair regrowth 15
AA NA NA 16
gioedema
sion
IV hydrocortisonic &
antihistamines
Disappeared 2 hours later 18
No treatment Less severe with each
injection
19
IV corticosteroids &
antihistamines
Disappeared within
24 hours and 36 hours,
respectively
20
Oral antihistamines &
corticosteroids
Disappeared within a
few days
21
ruption Acitretin 25 mg daily Minimal improvement
1 month later
24
ruption No treatment NA 24
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ﬁndings for our patient is the presence of eosinophilic inﬁltrates in
the acneiform and urticarial lesions. Although we did not perform
a biopsy of the AA lesions, eosinophilic inﬁltration is a common
pathologic feature of AA.27 Although the combination of adverse
cutaneous reactions observed here has not been previously repor-
ted, a common mechanism may be involved in the cause of all the
adverse reactions to adalimumab in our case.
Laga et al evaluated the histopathologic spectrum of psoriasi-
form skin eruptions associated with TNF-a inhibitor therapy, and
found that scattered to numerous eosinophils were observed in
most cases (14 out of 16 specimens).28 However, anti-TNF-a drugs
seem to elicit a spectrum of cutaneous reactions that go beyond the
classical eosinophilic-rich hypersensitivity reaction. The true
mechanism between eosinophilic inﬁltration and TNF-a blocking
remains to be fully determined. De Gannes and colleagues
proposed that there is cross-regulation between TNF-a and inter-
feron (IFN)-a, which may lead to an increase in IFN-a.29 They also
suggested that aberrant IFN-a expression in predisposed individ-
uals during anti-TNF-a therapy may contribute to psoriasiform skin
eruptions and lupus-like syndrome. Similarly, acne, AA, and urti-
caria have been observed in patients receiving IFN therapy.30e32We
propose that overexpression of IFN during anti-TNF-a therapy plays
a role in the pathogenesis of the diverse clinical spectrum of
cutaneous reactions in predisposed individuals and may partly
account for eosinophilic inﬁltration.
Some authors consider these adverse reactions a class effect of
anti-TNF-a agents.33 However, in our patient, the skin lesions
improved after changing to etanercept therapy. The different
immunosuppressive strength of these two biologics may account
for the difference. Moreover, differences in the mechanism of
reaction at injection sites have been reported for adalimumab
and etanercept.34 We suggest that some adverse cutaneous
reactions, such as psoriasiform eruptions, are a class effect,
whereas others, such as injection-site reactions, may be drug-
speciﬁc.
PPP is a challenging disease for which no therapeutic stan-
dard has yet been deﬁned; acitretin is the drug of choice
according to most recommendations. The difference between
PPP and psoriasis has long been debated, and some current
therapeutic guidelines do not recommend the use of biologics in
PPP because of inconsistent therapeutic responses and a possibly
higher risks of adverse cutaneous reactions.35e38 However, most
of the drugs used for psoriasis have been used for PPP. Some
authors have also suggested that concomitant use of biologic
agents and methotrexate has a synergic effect on psoriasis. We
thus used acitretin, ustekinumab, methotrexate, and low-dose
cyclosporine concomitantly for the patient because of the poor
response to previous biologics and the refractory nature of his
urticaria and PPP.
Ustekinumab is a new biologic that has been approved for the
treatment of moderate to severe plaque psoriasis in many coun-
tries. It is a fully human immunoglobulin G kappa monoclonal
antibody that binds to interleukin-12 and interleukin-23 and
subsequently reduces the activity of T-helper 17 cells. In a recent
case series available online, only one out of four patients with PPP
experienced good but slow efﬁcacy for ustekinumab, unlike the fast
onset of treatment response observed in plaque psoriasis.39 This
result is consistent with our experience.
In conclusion, this is a rare case of a patient who showed four
adverse cutaneous reactions concurrently following adalimumab
treatment for PPP. The pathological ﬁndings in our case suggest
a shared pathogenic mechanism, but further studies are necessary
to clarify the exact causes of adalimumab-related cutaneous side
effects. As the use of TNF-a antagonists continues to increase,recognition and management of such side effects will become
increasingly important.References
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